{"id":"sotagliflozin-high-dose","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"null","effect":"Ketoacidosis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT1 and SGLT2, sotagliflozin increases urinary glucose excretion, leading to improved glycemic control in patients with diabetes. This mechanism of action also has potential benefits for cardiovascular outcomes.","oneSentence":"Sotagliflozin is a dual inhibitor of SGLT1 and SGLT2, which helps to reduce glucose reabsorption in the kidneys and intestines.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:53:27.436Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 1 diabetes"},{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT07211802","phase":"PHASE3","title":"CKM For Safe Use of SGLT2i in Type 1 Diabetes","status":"NOT_YET_RECRUITING","sponsor":"University of California, San Diego","startDate":"2026-07-01","conditions":"Type 1 Diabetes (T1D)","enrollment":52},{"nctId":"NCT02421510","phase":"PHASE3","title":"Efficacy, Safety, and Tolerability Study of Sotagliflozin as Adjunct Therapy in Adult Patients With Type 1 Diabetes Mellitus Who Have Inadequate Glycemic Control With Insulin Therapy","status":"COMPLETED","sponsor":"Lexicon Pharmaceuticals","startDate":"2015-05","conditions":"Type 1 Diabetes Mellitus","enrollment":782}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Sotagliflozin High Dose","genericName":"Sotagliflozin High Dose","companyName":"University of California, San Diego","companyId":"university-of-california-san-diego","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Sotagliflozin is a dual inhibitor of SGLT1 and SGLT2, which helps to reduce glucose reabsorption in the kidneys and intestines. Used for Type 1 diabetes, Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}